Doctors from Sir Ganga Ram Hospital in New Delhi have successfully analysed the monoclonal antibody therapy on two Covid-19 patients. This therapy resulted into fast progression of symptoms within first seven days.
About the therapy
-
Two patients were administered REGCov2 (Casirivimab and Imdevimab). They started to produce resistance against SARS-CoV-2, recovered and then discharged within 12 hours of administration of doses.
-
A healthcare worker with high-grade fever, cough, myalgia, severe weakness, and leucopenia was administered REGCov2 on day six of the disease, according to the press release of the hospital.
-
This “antibody cocktail treatment” for coronavirus have potential to prevent case escalation from mild to severe, which requires hospitalisation in 70% of cases.
-
This therapy is most suited for “high-risk Covid-19 patients” in first 10 days of symptom onset and who meet any of listed criteria like age being 65 years or above.
What are Monoclonal Antibodies?
Monoclonal antibodies are identical copies of antibody that targets one specific antigen. They are made by cloning a unique white blood cell. All subsequent antibodies which are derived this way belongs to a unique parent cell. Monoclonal antibodies have monovalent affinity. They bind only to same epitope which is part of an antigen recognized by antibody). Bispecific monoclonal antibodies can also be made by increasing therapeutic targets of one monoclonal antibody to two epitopes.